Defining and Measuring Innovation in a Changing Biomedical Landscape
Washington Plaza Hotel • Washington, DC
October 14, 2015

Participant List

Murray Aitken  
Senior Vice President, IMS Health and Executive Director, IMS Institute for Healthcare Informatics

Naomi Aronson  
Executive Director, Clinical Evaluation, Innovation and Policy, Office of Clinical Affairs, Blue Cross and Blue Shield Association

Céline Audibert  
Director, European Market Research, Deerfield Institute

Marc Berger  
Vice President, Real World Data and Analytics, Pfizer

Ernst Berndt  
Louis E. Seley Professor in Applied Economics, Sloan School of Management, Massachusetts Institute of Technology

Robert Califf  
Deputy Commissioner for Medical Products and Tobacco, U.S. Food and Drug Administration

Jordan Chapman  
Coordinator, Science and Regulatory Affairs, Biotechnology Industry Organization

Rick Chapman  
Director of Health Economics, Institute for Clinical and Economic Review

Bill Chin  
Executive Vice President, Science and Regulatory Advocacy, Pharmaceutical Research and Manufacturers of America

Sarina Coates  
Research Assistant, Center for Health Policy, The Brookings Institution

Ryan Conrad  
Economist, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Gregory Daniel  
Managing Director, Evidence Development and Innovation, Center for Health Policy and Fellow, Economic Studies, The Brookings Institution

Jennifer Graff  
Vice President, Comparative Effectiveness Research, National Pharmaceutical Council

Robert Guidos  
Senior Advisor to the Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Jonathan Jarow  
Acting Director, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Amber Jessup  
Senior Economist, Office of Data Policy, Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services

Ken Kaitin  
Director, Tufts Center for the Study of Drug Development and Professor, Tufts University School of Medicine
Kirk Kerr
Economist, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Paul Kluetz
Acting Deputy Director, Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Michael Lanthier
Operations Research Analyst, Office of Planning, Office of the Commissioner, U.S. Food and Drug Administration

Jonathan Leff
Partner, Deerfield Management and Chairman, Deerfield Institute

Kimberly McCleary
Managing Director, FasterCures

Mark McClellan
Senior Fellow and Director, Health Care Innovation and Value Initiative, The Brookings Institution

Bernard Munos
Innovation Fellow, FasterCures

Bill Murray
President and Chief Executive Officer, Medical Device Innovation Consortium

Peter Neumann
Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts University and Professor of Medicine, Tufts University School of Medicine

Tomas Philipson
Daniel Levin Professor of Public Policy, Irving B. Harris Graduate School of Public Policy, The University of Chicago

Rajesh Ranganathan
Vice President, Science and Regulatory Advocacy, Pharmaceutical Research and Manufacturers of America

Morgan Romine
Research Associate, Center for Health Policy, The Brookings Institution

Janet Woodcock
Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Marta Wosinska
Director, Economics Staff, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration